3 citations
,
July 2024 in “Archives of Dermatological Research” This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.
1 citations
,
December 2017 in “Dermatology - Open Journal” This case study reports successful regression of alopecia areata in a female patient through DPCP immunotherapy supported by oral antihistamines and topical corticosteroids, suggesting indirect antihistamine effects on allergic inflammation may contribute to improvement.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.
36 citations
,
October 2002 in “The Journal of Dermatology” This study suggests that combining topical squaric acid dibutylester with other therapies may improve hair regrowth in patients with alopecia areata unresponsive to topical therapy alone.